ARTIVION, INC. (AORT) FY2025 10-K Annual Report
ARTIVION, INC. (AORT) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 18, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
ARTIVION, INC. FY2025 10-K Analysis
Business Overview
- • Core business model: Manufacturer and distributor of medical devices and implantable human tissues for cardiac and vascular surgery, focusing on aortic disease treatment
- • New product launch: Arcevo™ LSA Hybrid Stent Graft System introduced in EMEA and APAC in 2025, with US PMA trial ongoing, plus PerClot® hemostatic powder manufacturing started Q2 2023
Management Discussion & Analysis
- • Revenue $441.3M in 2025, up 14% YoY from $388.5M in 2024; constant currency increase 13%
- • Gross margin 64% in 2025, flat YoY despite 14% gross margin dollar growth to $284.2M
Risk Factors
- • Regulatory risk: Italian medical device overpayment repayment exposure $2.3M for 2019–2025 period under Ministerial Decree, potential further government assessment
- • Geopolitical risk: NEXUS products solely made in Israel amid Middle East conflicts, risking supply disruption from war, sanctions, or export controls
ARTIVION, INC. FY2025 Key Financial MetricsXBRL
Revenue
$441M
▲ +13.6% YoY
Net Income
$10M
▲ +173.1% YoY
Gross Margin
64.4%
▲ +37bp YoY
Operating Margin
7.6%
▼ -236bp YoY
Net Margin
2.2%
▲ +565bp YoY
ROE
2.2%
▲ +702bp YoY
Total Assets
$885M
▲ +12.1% YoY
EPS (Diluted)
$0.21
▲ +165.6% YoY
Operating Cash Flow
$40M
▲ +79.3% YoY
Source: XBRL data from ARTIVION, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on ARTIVION, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.